XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Net sales $ 700,062 $ 726,796
Cost of goods sold 296,502 326,169
Gross profit 403,560 400,627
Selling, general and administrative expense 197,594 225,853
Research and Development Expense 62,543 73,912
Segment profit (loss) 143,423 100,862
Interest expense 4,048 398
Foreign exchange (gains) losses, net (2,128) 71
Marketable Securities, Unrealized (Gain) Loss 4,545,117 (1,179,403)
Other Nonoperating Income (Expense) 32,597 17,407
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (4,371,017) 1,297,203
(Provision) benefit for income taxes 1,001,404 (319,789)
Net income attributable to Bio-Rad $ (3,369,613) $ 977,414
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad $ (112.57) $ 32.77
Weighted average common shares - basic 29,933 29,823
Diluted earnings per share:    
Net income per share diluted attributable to Bio-Rad $ (112.57) $ 32.38
Weighted average common shares - diluted 29,933 30,186